

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSENDER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.wopto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/560,789	12/15/2005	Shunji Kozaki	05856/HG	3009	
1933 7590 (30282098 FRISHAUF, HOLTZ, GOODMAN & CHICK, PC 220 Fifth Avenue			EXAM	EXAMINER	
			FORD, V	FORD, VANESSA L	
16TH Floor NEW YORK.	NY 10001-7708		ART UNIT PAPER NUMBER		
			1645		
			MAIL DATE	DELIVERY MODE	
			03/28/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) KOZAKI ET AL. 10/560,789 Office Action Summary Examiner Art Unit

	VANESSA L. FORD	1645	
The MAILING DATE of this communication appr Period for Reply	ears on the cover sheet with the	correspondence ad	dress
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTH's from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to play within the set or extended period for reply with by statute, Any reply received by the Office later than three months after the maining earned patent term adjustment. See 37 CFR 1.70(b).	TE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be till ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. mely filed the mailing date of this o D (35 U.S.C. § 133).	,
Status			
1) Responsive to communication(s) filed on 15 De 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowan closed in accordance with the practice under E.	action is non-final. ce except for formal matters, pro		e merits is
Disposition of Claims			
4) ⊠ Claim(s) <u>7-23</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ☒ Claim(s) <u>7-23</u> are subject to restriction and/or e			
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the c Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Example.	pted or b) objected to by the Irawing(s) be held in abeyance. Se on is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CF	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some *c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori	have been received. have been received in Applicat ty documents have been receiv (PCT Rule 17.2(a)).	ion No ed in this National	Stage
Attachment(s)			
	_		

1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

 Information Disclosure Statement(s) (PTO/SE/08) Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413) Paper No(s)/Mail Date.

5) Notice of Informal Patent Application 6) Other:

Application/Control Number: 10/560,789 Page 2

Art Unit: 1645

Election/Restriction

Applicant's preliminary amendment filed December 15, 2005 is acknowledged.
 Claims 1-6 have been canceled. Claims 7-23 have been added.

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- Group I Claim 7 is drawn to a method for inhibiting neuromuscular transmission comprising administering to a patient an effective amount of a M toxin (HA negative) of a type A toxin.
- Group II Claims 8-23 are drawn to a method for treating a disease caused by hypermyotonia comprising administering to a patient an effective amount of a M toxin (HA negative) of a type A toxin.
- 3. The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Application/Control Number: 10/560,789

Art Unit: 1645

Groups I and II lack novelty under PCT Article 33(2) as anticipated by (*Jpn. J. Med. Sci. Biol., 43, 219-231, 1990*). Tabita et al teach compositions comprising the M toxin, molecular weight 300 k (see the Abstract). Tabita et al teach that the Japan strains used to produce M toxins were Chiba-H, Kyoto-F and 7103-H (Table I, page 221). Tabita et al teach that all Japan strains were HA negative (see 223 and Table IV, page 226). The special technical feature linking the two Groups is the M toxin (HA negative) from *Clostridium botulinum* type A. Based on the teaching of Tabita et al, the special technical feature lacks novelty, therefore the other claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept. Thus, lack of unity exists.

Application/Control Number: 10/560,789

Art Unit: 1645

Conclusion

 Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vanessa L. Ford whose telephone number is (571)
 The examiner can normally be reached on 9 am- 6 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on (571) 272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Vanessa L. Ford/ Examiner, Art Unit 1645 March 22, 2008